822 A1A NORTH, PONTE VEDRA, FL
Shareholder votes
Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis
Annual Report to Security Holders
News
Reports First-Quarter 2025 Financial Results and Provides Corporate Update
News, Legal Opinion
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload
SEC Staff Correspondence